Bosentan therapy for pulmonary arterial hypertension

American Journal of Health-System Pharmacy

Volumn 61, Issue 11, 2004, Pages 1107-1119

  Cohen, Henry ^a,b   Chahine, Corinne ^c,d,e   Hui, Alan ^d,e,f   Mukherji, Rajat ^d  

^a LONG ISLAND UNIVERSITY   (United States)

^b KINGSBROOK JEWISH MEDICAL CENTER   (United States)

^c ST MICHAEL S MEDICAL CENTER   (United States)

^d Department of Medicine   (United States)

^e Arnold Marie Schwartz Coll P   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Anorexics; Bosentan; Diagnosis; Epidemiology; Hypertension; Hypotensive agents; Metabolism; Pediatrics; Toxicity

Indexed keywords

ANOREXIGENIC AGENT; BERAPROST; BOSENTAN; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; DRUG METABOLITE; ERYTHROMYCIN; GLIBENCLAMIDE; ILOPROST; KETOCONAZOLE; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; RIFAMPICIN; RO 478634; RO 485033; RO 641056; SILDENAFIL; SIMVASTATIN; SULFONAMIDE; UNCLASSIFIED DRUG; UNIPROST; WARFARIN; ANTIHYPERTENSIVE AGENT;

ALLERGIC REACTION; ANEMIA; ATRIUM SEPTOSTOMY; BLEEDING; BLOOD VESSEL WALL; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG METABOLISM; DYSPNEA; ELECTROCARDIOGRAPHY; EXERCISE TEST; FOOD DRUG INTERACTION; GRAPEFRUIT; HEART FAILURE; HEART SURGERY; HEMATOCRIT; HEMODYNAMICS; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOTENSION; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LACTATION; LIVER DISEASE; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PEDIATRICS; PERIPHERAL EDEMA; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RED WINE; REVIEW; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY; THROMBOSIS; VASOCONSTRICTION; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; ECONOMICS; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES;

EID: 5444239772     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.11.1107     Document Type: Review

References (77)

1. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107:216-23.
2. Rich S, ed. Executive summary from the World Symposium of Primary Pulmonary Hypertension. Evian, France; 1998.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997; 336:111-7.
4. National Heart, Lung, and Blood Institute. Primary pulmonary hypertension. www.nhlbi.nih.gov/health/public/lung/other/pph.htm (accessed 2004 Mar 8).
5. Chatterjee K, De Marco T, Alpert J. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med. 2002; 162:1925-33.
6. Thompson P, McRae C. Familial pulmonary hypertension: evidence of autosomal dominant inheritance. Br Heart J. 1970; 32:758-60.
7. Loyd JE, Primm RK, Newman JH. Familial pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984; 129:194-7.
8. Newman JH, Wheeler L, Lane KB et al. Mutation in the gene as a cause of primary pulmonary hypertension in large kindred. N Engl J Med. 2001; 345:319-24.
9. Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med. 2001; 345:367-71.
10. Rich S, Rubin L, Walker A et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000; 117:870-4.
11. Abenhaim L, Moride Y, Brenot F et al., for the International Primary Pulmonary Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996; 335:609-16.
12. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581-6.
13. Fishman AP. Aminorex to Fen/Phen: an epidemic foretold. Circulation. 1999; 99:156-61.
14. Follath F, Burkart F, Schweizer W. Drug-induced pulmonary hypertension. Br Med J. 1971; 1:265-6.
15. Reeve HL, Nelson DP, Archer SL et al. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol. 1999; 276:L213-9.
16. Salerni R, Rodnan GP, Leon DF. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med. 1977; 86:394-9.
17. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med. 1996; 17:17-33.
18. Speich R, Jenni R, Opravil M et al. Primary pulmonary hypertension in HIV infection. Chest. 1991; 100:1268-71.
19. Ungerer RG, Tashkin DP, Furst D et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983; 75:65-74.
20. Fowler NO, Wescott RN, Scott RC. Normal pressure in right heart and pulmonary artery. Am Heart J. 1953; 46:264-70.
21. Nicod P, Peterson K, Levine M et al. Pulmonary angiography in severe chronic pulmonary hypertension. Ann Intern Med. 1987; 107:565-8.
22. Olschewski H, Rose F, Grunig E et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med. 2001; 138:367-77.
23. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001; 108:1141-50.
24. Schulman LL, Grossman BA, Owen J. Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest. 1993; 104:1690-3.
25. Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327:70-5.
26. Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 1998; 114(3, suppl):208S-12S.
27. Yuan JX, Aldinger AM, Juhaszova M et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998; 98:1400-6.
28. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346:896-903. [Erratum, N Engl J Med. 2002; 346:1258.]
29. Levin ER. Endothelins. N Engl J Med. 1995; 333:356-63.
30. Ellahham SH, Charlon V, Abassi Z et al. Bosentan and the endothelin system in congestive heart failure. Clin Cardiol. 2000; 23:803-7.
31. Kaddoura S, Firth JD, Boheler KR et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation. 1996; 93:2068-79.
32. Muller DN, Mervaala EM, Schmidt F et al. Effect of bosentan on NF-kb, inflammation, and tissue factor in angiotensin II-induced end organ damage. Hypertension. 2000; 36:282-90.
33. Piacentini L, Gray M, Honbo NY et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol. 2000; 32:565-76.
34. Cozza EN, Chiou S, Gomez-Sanchez CE. Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 1992; 262:R85-9.
35. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328:1732-9.
36. Wei CM, Lerman A, Rodeheffer RJ et al. Endothelin in human congestive heart failure. Circulation. 1994; 89:1580-6.
37. Krum H, Viskoper RJ, Lacourciere Y et al. The effect of an endothelin-receptor antagonist, bosentan, on the blood pressure in patients with essential hypertension. N Engl J Med. 1998; 338:784-90.
38. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med. 1994; 33:579-82.
39. Macquin-Mavier I, Levame M, Istin N et al. Mechanisms of endothelin-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther. 1989; 250:740-5.
40. Luscher TF, Baston M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000; 102:2434-40.
41. Tracleer (bosentan) package insert. South San Francisco, CA: Actelion Pharmaceuticals; 2001.
42. Ioselevich A, Nogid B, Rozenfeld V. Endothelin receptor antagonism: focus on bosentan. P&T. 2001; 26:365-7.
43. Clozel M, Breu V, Gray GA et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994; 270:228-35.
44. Williamson DJ, Wallman L, Jones R et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000; 102:411-8.
45. Chen SJ, Chen YF, Meng QC et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995; 79:2122-31.
46. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995; 115:191-7.
47. Weber C, Schmitt R, Birnboeck H et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996; 60:124-37.
48. Dingemanse J, Bodin F, Weidekamm E et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2002; 42:283-9.
49. Weber C, Schmitt R, Birnboeck H et al. Multiple-dose pharmacokinetics, safety and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999; 39:703-14.
50. Weber C, Gasser R, Hopfgartner G. Absorption, excretion and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999; 27:810-5.
51. Dingemanse J, van Giersbergen PL. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual receptor antagonist. Int J Clin Pharmacol Ther. 2002; 40:310-6.
52. Binet I, Wallnofer A, Weber C et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000; 57:224-31.
53. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001; 358:1119-23.
54. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14:377-81.
55. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest. 1993; 92:17-24.
56. Fattinger K, Funk C, Pantze M et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001; 69:223-31.
57. Data on file. Actelion Ltd. South San Francisco, CA; 2002.
58. Shear NH, Spielberg SP, Grant DM et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986; 105:179-84.
59. Tilles S. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J. 2001; 94:817-24.
60. Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol. 1988; 25:1347-54.
61. Barst RJ, Ivy D, Dingemanse J et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003; 73:372-82.
62. Weber C, Banken L, Birnboeck H. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol. 1999; 47:701-6.
63. Van Giersbergen PL, Treiber A, Clozel M et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther. 2002; 71:253-62.
64. Van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002; 53:589-95.
65. Dingemanse J, Schaarschmidt D, van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Br J Clin Pharmacol. 2002; 53:547P. Abstract.
66. Weber C, Banken L, Birnboeck H. Effect of the endothelin-receptor antagonist bosentan on the pharmacodynamics of warfarin. J Clin Pharmacol. 1990; 39:847-54.
67. Thompson CA. Bosentan enters market with risk management program. Am J Health-Syst Pharm. 2002; 59:506. News.
68. Barst R, Rubin L, Long W et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334:296-301.
69. McLaughlin VV, Genthner DE, Panella MM et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998; 338:273-7.
70. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med. 2002; 165:800-4.
71. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000; 342:1866-70.
72. Nagaya N, Uematsu M, Okano Y et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34:1188-92.
73. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327:76-81.
74. Stiebellenher L, Petkov V, Vonbank K et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003; 134:1293-5.
75. Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70:580-7.
76. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med. 2001; 22:547-60.
77. Trulock EP. Lung transplantation for primary pulmonary hypertension. Clin Chest Med. 2001; 22:583-92.